Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection.

Laird ME, Mohsen A, Duffy D, Mamdouh R, LeFouler L, Casrouge A, El-Daly M, Rafik M, Abdel-Hamid M, Soulier A, Pawlotsky JM, Hézode C, Rosa I, Renard P, Mohamed MK, Bonnard P, Izopet J, Mallet V, Pol S, Albert ML, Fontanet A.

J Hepatol. 2014 Oct;61(4):770-6. doi: 10.1016/j.jhep.2014.05.040. Epub 2014 Jun 4.

PMID:
24905490
2.

Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.

Sticchi L, Di Biagio A, Sartini M, Rappazzo E, Nicolini LA, Cenderello G, Valle C, Azzola E, Grasso A, De Leo P, Boldrini A, Setti M, Prinapori R, Lorusso C, Bruzzone B, Icardi G; Ligurian HIV Network.

New Microbiol. 2015 Oct;38(4):499-509. Epub 2015 Oct 20.

3.

Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients.

Labarga P, Soriano V, Caruz A, Poveda E, Di Lello FA, Hernandez-Quero J, Moreno S, Bernal E, Miró JM, Leal M, Gutierrez F, Portilla J, Pineda JA; CoRIS.

AIDS. 2011 Mar 27;25(6):761-6. doi: 10.1097/QAD.0b013e32834488e7. Erratum in: AIDS. 2013 Jul 31;27(12):2001. Di Lello, Frederico [corrected to Di Lello, Federico A].

PMID:
21378537
4.

[IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].

Pár A, Pár G, Tornai I, Szalay F, Várszegi D, Fráter E, Papp M, Lengyel G, Fehér J, Varga M, Gervain J, Schuller J, Nemes Z, Péterfi Z, Tusnádi A, Hunyady B, Haragh A, Szinku Z, Pálinkás L, Berki T, Vincze A, Kisfali P, Melegh B.

Orv Hetil. 2013 Aug 11;154(32):1261-8. doi: 10.1556/OH.2013.29680. Hungarian.

PMID:
23916907
5.

Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.

Naggie S, Osinusi A, Katsounas A, Lempicki R, Herrmann E, Thompson AJ, Clark PJ, Patel K, Muir AJ, McHutchison JG, Schlaak JF, Trippler M, Shivakumar B, Masur H, Polis MA, Kottilil S.

Hepatology. 2012 Aug;56(2):444-54. doi: 10.1002/hep.25647. Epub 2012 Jul 2.

6.

IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients.

Zeremski M, Dimova RB, Makeyeva J, Sipley JD, Jacobson IM, Rennert H, Talal AH.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):9-16. doi: 10.1097/QAI.0b013e31828323c1.

PMID:
23274935
7.

LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.

Rivero-Juarez A, Camacho A, Caruz A, Neukam K, Gonzalez R, Di Lello FA, Perez-Camacho I, Mesa P, Torre-Cisneros J, Peña J, Pineda JA, Rivero A.

AIDS. 2012 May 15;26(8):1009-15. doi: 10.1097/QAD.0b013e3283528b1c.

PMID:
22382144
8.

IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.

Asselah T, De Muynck S, Broët P, Masliah-Planchon J, Blanluet M, Bièche I, Lapalus M, Martinot-Peignoux M, Lada O, Estrabaud E, Zhang Q, El Ray A, Vidaud D, Ripault MP, Boyer N, Bedossa P, Valla D, Vidaud M, Marcellin P.

J Hepatol. 2012 Mar;56(3):527-32. doi: 10.1016/j.jhep.2011.09.008. Epub 2011 Sep 25.

PMID:
21951981
9.

Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection.

Keane C, O'Shea D, Reiberger T, Peck-Radosavljevic M, Farrell G, Bergin C, Gardiner CM.

PLoS One. 2013 Jun 24;8(6):e66831. doi: 10.1371/journal.pone.0066831. Print 2013.

10.

Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV.

Rallón NI, Soriano V, Naggie S, Restrepo C, McHutchison J, Vispo E, Benito JM.

J Antimicrob Chemother. 2012 May;67(5):1246-9. doi: 10.1093/jac/dkr598. Epub 2012 Feb 1.

11.

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.

Suppiah V, Gaudieri S, Armstrong NJ, O'Connor KS, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Dore GJ, Irving WL, Powell E, Hellard M, Riordan S, Matthews G, Sheridan D, Nattermann J, Smedile A, Müller T, Hammond E, Dunn D, Negro F, Bochud PY, Mallal S, Ahlenstiel G, Stewart GJ, George J, Booth DR; International Hepatitis C Genetics Consortium (IHCGC).

PLoS Med. 2011 Sep;8(9):e1001092. doi: 10.1371/journal.pmed.1001092. Epub 2011 Sep 13.

12.

Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.

Rivero-Juárez A, Camacho Espejo A, Perez-Camacho I, Neukam K, Caruz A, Mira JA, Mesa P, García-Lázaro M, Torre-Cisneros J, Pineda JA, Rivero A.

J Antimicrob Chemother. 2012 Jan;67(1):202-5. doi: 10.1093/jac/dkr439. Epub 2011 Oct 11.

PMID:
21990051
13.

Relating the outcome of HCV infection and different host SNP polymorphisms in a Majorcan population coinfected with HCV-HIV and treated with pegIFN-RBV.

Matas M, Picornell A, Cifuentes C, Payeras A, Homar F, González-Candelas F, López-Labrador FX, Moya A, Ramon C, Castro JA.

Int Microbiol. 2014 Mar;17(1):11-20.

14.

[Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients].

Liu B, Cai WP, Hu FY, Xu M, Lan Y, Tang XP.

Zhonghua Gan Zang Bing Za Zhi. 2013 Nov;21(11):829-33. doi: 10.3760/cma.j.issn.1007-3418.2013.11.008. Chinese.

PMID:
24331692
15.
16.

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.

Sarrazin C, Susser S, Doehring A, Lange CM, Müller T, Schlecker C, Herrmann E, Lötsch J, Berg T.

J Hepatol. 2011 Mar;54(3):415-21. doi: 10.1016/j.jhep.2010.07.041. Epub 2010 Sep 22.

PMID:
21112657
17.

Impact of Il28b-related single nucleotide polymorphisms on liver transient elastography in chronic hepatitis C infection.

Ydreborg M, Westin J, Rembeck K, Lindh M, Norrgren H, Holmberg A, Wejstål R, Norkrans G, Cardell K, Weiland O, Lagging M.

PLoS One. 2013 Nov 14;8(11):e80172. doi: 10.1371/journal.pone.0080172. eCollection 2013.

18.

Treatment optimization and prediction of HCV clearance in patients with acute HCV infection.

Mangia A, Santoro R, Copetti M, Massari M, Piazzolla V, Spada E, Cappucci G, Missale G, Mottola L, Agostinacchio E, Mauro Ld, Zuccaro O, Maio P, Pellegrini F, Folgori A, Ferrari C.

J Hepatol. 2013 Aug;59(2):221-8. doi: 10.1016/j.jhep.2013.04.007. Epub 2013 Apr 12.

PMID:
23587473
19.

IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients.

Payer BA, Reiberger T, Aberle J, Ferenci P, Holzmann H, Rieger A, Peck-Radosavljevic M; Vienna HIV-HCV study group.

Eur J Clin Invest. 2012 Jun;42(6):599-606. doi: 10.1111/j.1365-2362.2011.02623.x. Epub 2011 Nov 25.

PMID:
22117591
20.

IL28B gene polymorphisms and US liver fatty changes in patients who spontaneously cleared hepatitis C virus infection.

Taliani G, Spaziante M, Biliotti E, Borro M, Palazzo D, Grieco S, Franchi C, Iaiani G, Furlan C, Gallinaro V, Simmaco M.

PLoS One. 2013 Aug 1;8(8):e67301. doi: 10.1371/journal.pone.0067301. Print 2013.

Supplemental Content

Support Center